ESMO Immuno-Oncology Congress 2025
Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Novel combination shows survival benefits in high-risk gastric/gastro-oesophageal junction cancer
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study
Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
Exploring synergy to keep the immunotherapy flame alight
2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy